Skip to main content
Erschienen in: Diabetologia 4/2013

01.04.2013 | Review

Revisiting the links between glycaemia, diabetes and cardiovascular disease

verfasst von: N. Sattar

Erschienen in: Diabetologia | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Whilst the interplay between type 2 diabetes and cardiovascular disease (CVD) has been recognised for many years, recent analyses of existing studies have helped refine several aspects of this relationship with relevance to clinical practice. First, recent data demonstrate that fasting glucose is not linearly related to CVD risk in those without diabetes; rather, risk levels escalate (modestly at first) only beyond specific glucose thresholds. Consequently, glucose-based measures may not necessarily enhance CVD risk prediction in those without diabetes. Second, other data confirm that new-onset diabetes is not a post-myocardial infarction ‘risk equivalent’ state and that, on average, several years of diabetes duration is needed to attain this level of risk. Third, meta-analyses and systemic reviews have confirmed that diabetes increases CVD risk by around twofold on average and this risk is subject to wide variation, being lowest in those newly diagnosed and highest in those with existing vascular disease, proteinuria or renal disease. Fourth, meta-analyses of major glucose-lowering trials suggest that, whilst glucose-lowering lessens vascular risk, risk reduction arising from statins and blood pressure-lowering is greater. Fifth, statins increase diabetes risk, albeit modestly, adding to the emerging concept that some agents that primarily target CVD risk may be diabetogenic, and vice versa. Finally, arising in part from the latter observation, as well as an understanding that CVD and diabetes risk overlap in some individuals but not others, the case for combined CVD/diabetes risk screening (generally using non-fasting lipids and HbA1c), has gained strength.
Literatur
1.
Zurück zum Zitat Freeman DJ, Norrie J, Caslake MJ et al (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51:1596–1600PubMedCrossRef Freeman DJ, Norrie J, Caslake MJ et al (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51:1596–1600PubMedCrossRef
2.
Zurück zum Zitat Preiss D, Welsh P, Murray HM et al (2010) Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up. Eur Heart J 31:1230–1236PubMedCrossRef Preiss D, Welsh P, Murray HM et al (2010) Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up. Eur Heart J 31:1230–1236PubMedCrossRef
3.
Zurück zum Zitat Emerging Risk Factors Collaboration, Sarwar N, Gao P et al (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215–2222PubMedCrossRef Emerging Risk Factors Collaboration, Sarwar N, Gao P et al (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215–2222PubMedCrossRef
4.
Zurück zum Zitat Sarwar N, Aspelund T, Eiriksdottir G, et al (2010) Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Med 7:e1000278 Sarwar N, Aspelund T, Eiriksdottir G, et al (2010) Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Med 7:e1000278
5.
Zurück zum Zitat Simmons RK, Sharp S, Boekholdt SM et al (2008) Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events? Arch Intern Med 168:1209–1216PubMedCrossRef Simmons RK, Sharp S, Boekholdt SM et al (2008) Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events? Arch Intern Med 168:1209–1216PubMedCrossRef
6.
Zurück zum Zitat Selvin E, Steffes MW, Zhu H et al (2010) Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 362:800–811PubMedCrossRef Selvin E, Steffes MW, Zhu H et al (2010) Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 362:800–811PubMedCrossRef
7.
Zurück zum Zitat Schöttker B, Müller H, Rothenbacher D, Brenner H (2013) Fasting plasma glucose and HbA1c in cardiovascular risk prediction: a sex-specific comparison in individuals without diabetes mellitus. Diabetologia 56:92–100 Schöttker B, Müller H, Rothenbacher D, Brenner H (2013) Fasting plasma glucose and HbA1c in cardiovascular risk prediction: a sex-specific comparison in individuals without diabetes mellitus. Diabetologia 56:92–100
8.
Zurück zum Zitat Hippisley-Cox J, Coupland C, Vinogradova Y et al (2008) Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 336:1475–1482PubMedCrossRef Hippisley-Cox J, Coupland C, Vinogradova Y et al (2008) Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 336:1475–1482PubMedCrossRef
9.
Zurück zum Zitat Wannamethee SG, Papacosta O, Whincup PH et al (2011) The potential for a two-stage diabetes risk algorithm combining non-laboratory-based scores with subsequent routine non-fasting blood tests: results from prospective studies in older men and women. Diabet Med 28:23–30PubMedCrossRef Wannamethee SG, Papacosta O, Whincup PH et al (2011) The potential for a two-stage diabetes risk algorithm combining non-laboratory-based scores with subsequent routine non-fasting blood tests: results from prospective studies in older men and women. Diabet Med 28:23–30PubMedCrossRef
11.
Zurück zum Zitat Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234PubMedCrossRef Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234PubMedCrossRef
12.
Zurück zum Zitat Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N (2011) Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med 171:404–410PubMedCrossRef Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N (2011) Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med 171:404–410PubMedCrossRef
13.
Zurück zum Zitat Evans JM, Wang J, Morris AD (2002) Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 324:939–942PubMedCrossRef Evans JM, Wang J, Morris AD (2002) Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 324:939–942PubMedCrossRef
14.
Zurück zum Zitat Preiss D, Sattar N, McMurray JJ (2011) A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. Am Heart J 161:210–219PubMedCrossRef Preiss D, Sattar N, McMurray JJ (2011) A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. Am Heart J 161:210–219PubMedCrossRef
15.
Zurück zum Zitat Tonelli M, Muntner P, Lloyd A et al (2012) Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 380:807–814PubMedCrossRef Tonelli M, Muntner P, Lloyd A et al (2012) Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 380:807–814PubMedCrossRef
16.
Zurück zum Zitat UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef
17.
Zurück zum Zitat Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR (2008) Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359:1565–1576PubMedCrossRef Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR (2008) Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359:1565–1576PubMedCrossRef
18.
Zurück zum Zitat The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559CrossRef The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559CrossRef
19.
Zurück zum Zitat The ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRef The ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRef
20.
Zurück zum Zitat Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139PubMedCrossRef Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139PubMedCrossRef
21.
Zurück zum Zitat Ray KK, Seshasai SR, Wijesuriya S et al (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373:1765–1772PubMedCrossRef Ray KK, Seshasai SR, Wijesuriya S et al (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373:1765–1772PubMedCrossRef
22.
Zurück zum Zitat Control Group, Turnbull FM, Abraira C et al (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52:2288–2298PubMedCrossRef Control Group, Turnbull FM, Abraira C et al (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52:2288–2298PubMedCrossRef
23.
Zurück zum Zitat Yudkin JS, Richter B (2009) Intensive glucose control and cardiovascular outcomes. Lancet 374:522PubMedCrossRef Yudkin JS, Richter B (2009) Intensive glucose control and cardiovascular outcomes. Lancet 374:522PubMedCrossRef
24.
Zurück zum Zitat Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591PubMedCrossRef Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591PubMedCrossRef
25.
Zurück zum Zitat Zoungas S, Chalmers J, Ninomiya T et al (2012) Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 55:636–643PubMedCrossRef Zoungas S, Chalmers J, Ninomiya T et al (2012) Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 55:636–643PubMedCrossRef
26.
Zurück zum Zitat ORIGIN Trial Investigators, Gerstein HC, Bosch J et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319–328PubMedCrossRef ORIGIN Trial Investigators, Gerstein HC, Bosch J et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319–328PubMedCrossRef
27.
Zurück zum Zitat Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N et al (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302:1993–2000PubMedCrossRef Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N et al (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302:1993–2000PubMedCrossRef
28.
Zurück zum Zitat Goldfine AB, Kaul S, Hiatt WR (2011) Fibrates in the treatment of dyslipidemias—time for a reassessment. N Engl J Med 365:481–484PubMedCrossRef Goldfine AB, Kaul S, Hiatt WR (2011) Fibrates in the treatment of dyslipidemias—time for a reassessment. N Engl J Med 365:481–484PubMedCrossRef
29.
Zurück zum Zitat Sattar N (2008) Why metabolic syndrome criteria have not made prime time: a view from the clinic. Int J Obes (Lond) 32(Suppl 2):S30–S34CrossRef Sattar N (2008) Why metabolic syndrome criteria have not made prime time: a view from the clinic. Int J Obes (Lond) 32(Suppl 2):S30–S34CrossRef
30.
Zurück zum Zitat Ghouri N, Preiss D, Sattar N (2010) Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 52:1156–1161PubMedCrossRef Ghouri N, Preiss D, Sattar N (2010) Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 52:1156–1161PubMedCrossRef
31.
Zurück zum Zitat Sattar N, McConnachie A, Shaper AG et al (2008) Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 371:1927–1935PubMedCrossRef Sattar N, McConnachie A, Shaper AG et al (2008) Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 371:1927–1935PubMedCrossRef
32.
Zurück zum Zitat Simmons RK, Alberti KG, Gale EA et al (2010) The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 53:600–605PubMedCrossRef Simmons RK, Alberti KG, Gale EA et al (2010) The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 53:600–605PubMedCrossRef
33.
Zurück zum Zitat Preiss D, Tikkanen MJ, Welsh P et al (2012) Lipid-modifying therapies and risk of pancreatitis. A meta-analysis. JAMA 304:804–811 Preiss D, Tikkanen MJ, Welsh P et al (2012) Lipid-modifying therapies and risk of pancreatitis. A meta-analysis. JAMA 304:804–811
34.
Zurück zum Zitat Wannamethee SG, Papacosta O, Lawlor DA et al (2012) Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women’s Heart Health Study. Diabetologia 55:80–87PubMedCrossRef Wannamethee SG, Papacosta O, Lawlor DA et al (2012) Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women’s Heart Health Study. Diabetologia 55:80–87PubMedCrossRef
35.
Zurück zum Zitat Logue J, Walker JJ, Colhoun HM et al (2011) Do men develop type 2 diabetes at lower body mass indices than women? Diabetologia 54:3003–3006PubMedCrossRef Logue J, Walker JJ, Colhoun HM et al (2011) Do men develop type 2 diabetes at lower body mass indices than women? Diabetologia 54:3003–3006PubMedCrossRef
36.
Zurück zum Zitat Sourij H, Holman RR (2012) Women develop diabetes at higher BMIs than men. Diabetologia 55:855–856PubMedCrossRef Sourij H, Holman RR (2012) Women develop diabetes at higher BMIs than men. Diabetologia 55:855–856PubMedCrossRef
37.
Zurück zum Zitat Paul S, Thomas G, Majeed A, Khunti K, Klein K (2012) Women develop type 2 diabetes at a higher body mass index than men. Diabetologia 55:1556–1557PubMedCrossRef Paul S, Thomas G, Majeed A, Khunti K, Klein K (2012) Women develop type 2 diabetes at a higher body mass index than men. Diabetologia 55:1556–1557PubMedCrossRef
38.
Zurück zum Zitat Freeman DJ, Norrie J, Sattar N et al (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103:357–362PubMedCrossRef Freeman DJ, Norrie J, Sattar N et al (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103:357–362PubMedCrossRef
39.
Zurück zum Zitat Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207PubMedCrossRef Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207PubMedCrossRef
40.
Zurück zum Zitat Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375:735–742PubMedCrossRef Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375:735–742PubMedCrossRef
41.
Zurück zum Zitat Preiss D, Seshasai SR, Welsh P et al (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305:2556–2564PubMedCrossRef Preiss D, Seshasai SR, Welsh P et al (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305:2556–2564PubMedCrossRef
42.
Zurück zum Zitat Preiss D, Khunti K, Sattar N (2011) Combined cardiovascular and diabetes risk assessment in primary care. Diabet Med 28:19–22PubMedCrossRef Preiss D, Khunti K, Sattar N (2011) Combined cardiovascular and diabetes risk assessment in primary care. Diabet Med 28:19–22PubMedCrossRef
43.
Zurück zum Zitat Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829–841PubMedCrossRef Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829–841PubMedCrossRef
44.
Zurück zum Zitat Gregg EW, Cheng YJ, Saydah S et al (2012) Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey. Diabetes Care 35:1252–1257PubMedCrossRef Gregg EW, Cheng YJ, Saydah S et al (2012) Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey. Diabetes Care 35:1252–1257PubMedCrossRef
45.
Zurück zum Zitat Ford ES (2011) Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the U.S.: findings from the National Health and Nutrition Examination Survey, 1999–2008. Diabetes Care 34:1337–1343PubMedCrossRef Ford ES (2011) Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the U.S.: findings from the National Health and Nutrition Examination Survey, 1999–2008. Diabetes Care 34:1337–1343PubMedCrossRef
46.
Zurück zum Zitat Harron KL, Feltbower RG, McKinney PA, Bodansky HJ, Campbell FM, Parslow RC (2011) Rising rates of all types of diabetes in south Asian and non-south Asian children and young people aged 0–29 years in West Yorkshire, UK, 1991–2006. Diabetes Care 34:652–654PubMedCrossRef Harron KL, Feltbower RG, McKinney PA, Bodansky HJ, Campbell FM, Parslow RC (2011) Rising rates of all types of diabetes in south Asian and non-south Asian children and young people aged 0–29 years in West Yorkshire, UK, 1991–2006. Diabetes Care 34:652–654PubMedCrossRef
47.
Zurück zum Zitat Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053PubMedCrossRef Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053PubMedCrossRef
48.
Zurück zum Zitat Looker HC, Nyangoma SO, Cromie D et al (2012) Diabetic retinopathy at diagnosis of type 2 diabetes in Scotland. Diabetologia 55:2335–2342PubMedCrossRef Looker HC, Nyangoma SO, Cromie D et al (2012) Diabetic retinopathy at diagnosis of type 2 diabetes in Scotland. Diabetologia 55:2335–2342PubMedCrossRef
Metadaten
Titel
Revisiting the links between glycaemia, diabetes and cardiovascular disease
verfasst von
N. Sattar
Publikationsdatum
01.04.2013
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 4/2013
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-012-2817-5

Weitere Artikel der Ausgabe 4/2013

Diabetologia 4/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.